Transcode Therapeutics Inc
RNAZ
查看詳細走勢圖
7.380USD
-0.150-1.99%
收盤 12/24, 13:00（美東）報價延遲15分鐘
6.15M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-1.99%
5天
-12.77%
1月
-18.45%
6月
-5.26%
今年開始到現在
-92.18%
1年
-92.51%
查看詳細走勢圖
TradingKey Transcode Therapeutics Inc股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值合理，機構持股佔比非常高，近一個月多位分析師給出公司評級為。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Transcode Therapeutics Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
0
分析師
--
評級
10.000
目標均價
+2266.86%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Transcode Therapeutics Inc亮點
亮點風險
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Transcode Therapeutics Inc簡介
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
公司代碼RNAZ
公司Transcode Therapeutics Inc
CEOCalais (Philippe P)
網址https://www.transcodetherapeutics.com/
常見問題
Transcode Therapeutics Inc(RNAZ)的當前股價是多少？
Transcode Therapeutics Inc(RNAZ)的當前股價是 7.380。
Transcode Therapeutics Inc 的股票代碼是什麼？
Transcode Therapeutics Inc的股票代碼是RNAZ。
Transcode Therapeutics Inc股票的52週最高點是多少？
Transcode Therapeutics Inc股票的52週最高點是468.440。
Transcode Therapeutics Inc股票的52週最低點是多少？
Transcode Therapeutics Inc股票的52週最低點是6.148。
Transcode Therapeutics Inc的市值是多少？
Transcode Therapeutics Inc的市值是6.15M。
Transcode Therapeutics Inc的淨利潤是多少？
Transcode Therapeutics Inc的淨利潤為-16.82M。
現在Transcode Therapeutics Inc(RNAZ)的股票是買入、持有還是賣出？
根據分析師評級，Transcode Therapeutics Inc(RNAZ)的總體評級為--，目標價格為10.000。
Transcode Therapeutics Inc(RNAZ)股票的每股收益（EPS TTM）是多少
Transcode Therapeutics Inc(RNAZ)股票的每股收益（EPS TTM）是-238.843。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
